Publications

cemka > Publications

Classer les publications sur l'année

  • Économie de la santĂ©

    Economic Evaluation of Telerehabilitation: Systematic Literature Review of Cost-Utility Studies.

    BAFFERT S, HADOUIRI N, FABRON C, BURGY F, CASSANY A, KEMOUN G.

    JMIR Rehabil Assist Technol ; 2023; 10 : e47172

  • Pharmaco-EpidĂ©miologie

    Vitiligo Patient Population and Disease Burden in France: VIOLIN Study Results From the CONSTANCES Cohort.

    EZZEDINE K, SENESCHAL J, DA SILVA A, PREAUBERT N, LAMBLIN A, DELATTRE C, EMERY C, NEVORET C, FINZI J, BOUEE S, PASSERON T.

    J Eur Acad Dermatol Venereol ; 2023;7 : 2159–2160

  • SantĂ© Publique et EpidĂ©miologie

    Evaluation quantitatives des ExpĂ©rimentations art.51 : catalyseurs de la culture d’Ă©valuation basĂ©e sur les donnĂ©es de santĂ© en France

    BESSOU A, BUGNARD F, DE NEUVILLE B, DUBURCQ A, GRENIER B et les Membres du groupe de travail RWD de l’AFCROs.

    AFCROs ;

  • Pharmaco-EpidĂ©miologie

    Treatment Patterns and Survival in Patients with Intermediate, Advanced, or Terminal Stage of Hepatocellular Carcinoma in France over the Period 2015-2017: A Real-Life Study

    BLANC J-F, LAURENDEAU C, DE ZELICOURT M, DHAOUI M, KELKOULI N, FAGNANI F, MATHURIN P.

    GastroHep ; 2023; Article ID 5800168, 12 pages

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Health status and comorbidities of adult patients with phenylketonuria (PKU) in France with a focus on early-diagnosed patients – A nationwide study of health insurance claims data

    CHARRIERE S, MAILLOT F, BOUEE S, DOUILLARD C, JACOB C, MAREN SCHNEIDER K, THEIL J, ARNOUX J-B.

    Molecular Genetics and Metabolism ; 2023;139(3):107625

  • Pharmaco-EpidĂ©miologie

    Point-of-Care Testing for SARS-CoV-2 : A Prospective Study in a Primary Health Centre

    DANIELS R, COTTIN J, KHANAFER N

    Diagnostics ; 2023;13(11):1888

  • SantĂ© Publique et EpidĂ©miologie

    Overview of organisational methods of primary cervical lesion screening programmes that use human papillomavirus testing.

    MARCHADIER A, BEZANNIER L,  BARRE-PIERREL S, MANCEAU A,  ABADIE A, DETOURNAY B.

    J Med Screen ; 2023;9691413231158932

  • Pharmaco-EpidĂ©miologie

    Asthma burden according to treatment steps in the French population-based cohort CONSTANCES.

    ROCHE N, NADIF R, FABRY-VENDRAND C, PILLOT L, THABUT G, TEISSIER C, BOUEE S, GOLDBERG M, ZINS M.

    Respir Med ; 2023;206:107057

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: A retrospective database analysis

    MATHURIN P, DE ZELICOURT M, LAURENDEAU C, DHAOUI M, KELKOULI N, BLANC J-F.

    Clin Res Hepatol Gastroenterol ; 2023;47(5):102124

  • Pharmaco-EpidĂ©miologie

    Medico-economic comparison of two anticoagulant treatment strategies: Vitamin K antagonists vs. direct oral anticoagulants in older adults in nursing homes in France. The « MIKADO » study

    PISICA-DONOSE G, PICCOLI M, GENET B, BOUEE S, BERECHET S, BERECHET I, DACASA CORTES A, ATSAMENA S, BAYLE C, BADESCU M, CATELAIN F, KERMECHE L, MERLIER I, RAKOTONIARY S, SAVIN V, VIDAL A, VIDAL J-S, HANON O.

    PLoS One  ; 2023;18(4):e0283604

  • SantĂ© Publique et EpidĂ©miologie

    Organisational Impact of a Remote Patient Monitoring System for Heart Failure Management: The Experience of 29 Cardiology Departments in France.

    ALAMI S, COUROUVE L, LANCMAN G, GOMIS P, AL-HAMOUD G, LAURELLI C, PASCHE H, CHATELLIER G, MERCIER G, ROUBILLE F, DELVAL C, DURAND-ZALESKI I.

    Int J Environ Res Public Health ; 2023;20(5):4366

  • Pharmaco-EpidĂ©miologie

    The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.

    DE SEZE J, SUCHET L, MEKIES C, MANCHON E, LABAUGE P, GUENNOC AM, DEFER G, CLAVELOU P, CASTELNOVO G, BOURRE B, BENSA-KOSCHER C, AL KHEDR A, LE MAO J, VILLEMUR L, BOUEE S, LUCIANI L, VERMERSCH P.

    Neurol Ther ; 2023;12(2):351-369

  • Autres

    DonnĂ©es et preuves en vie rĂ©elle dans l’évaluation des technologies de santĂ© : dans quels cas sont-elles complĂ©mentaires,substitutives, ou les seules sources de donnĂ©es par rapport aux essais cliniques ?

    DE POUVOURVILLE G, ARMOIRY X, LAVOREL A, BILBAULT P, MAUGENDRE P, BENSIMON L, BEZIZ D, BLIN P, BORGET I, BOUEE S, COLLIGNON C, DERVAUX B, DURAND-ZALESKI I, JULIEN M, DE LEOTOING L, MAJED L, MARTELLI N, SEJOURNE T, VIPREY M.

    Therapie ; 2023;78(1):66-80

  • Pharmaco-EpidĂ©miologie

    Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: insights from the ODYSSEY APPRISE study.

    HENRY P, CARIOU B, FARNIER M, LAKHDARI SL, DETOURNAY B.

    Arch Cardiovasc Dis ; 2023;116(1):3-8

  • Économie de la santĂ©

    Influence of geographic access and socioeconomic characteristics on breast cancer outcomes: A systematic review.

    CONTI B, BOCHATON A, CHARREIRE H, KITZIS-BONSANG H, DESPRÈS C, BAFFERT S, NGÔ C.

    PLoS One ; 2022;17(7):e0271319